Skip NavigationSkip to Content
Return Return to Search Results

GATA2-deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in humans

  1. Author:
    Desai, Avanti
    Sowerwine, Kathryn
    Liu, Yihui
    Lawrence, Monica G
    Chovanec, Jack
    Hsu, Amy P
    O'Connell, Michael P
    Kim, Jiwon
    Boris, Lisa
    Jones,Nina
    Wisch, Laura
    Eisch, Robin R
    Carter, Melody C
    Komarow, Hirsh D
    Zerbe, Christa
    Milner, Joshua D
    Maric, Irina
    Sun, Xiaoping
    Lee, Chyi-Chia R
    Tunc, Ilker
    Pirooznia, Mehdi
    Stone, Kelly D
    Holland, Steven M
    Metcalfe, Dean D
    Lyons, Jonathan J

  2. Author Address

    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Division of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia, Charlottesville, VA., Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD., Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute., Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD., Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Bioinformatics and Computational Biology Core, NHLBI, NIH., Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. Electronic address: jonathan.lyons@nih.gov.,
    1. Year: 2019
    2. Date: AUG
    3. Epub Date: 2019 05 15
  2. Journal: The Journal of allergy and clinical immunology
    1. 144
    2. 2
    3. Pages: 613-+
  4. Type of Article: Article
  5. ISSN: 0091-6749
  1. Abstract:

    GATA2 deficient patients have a low prevalence of allergic disease resulting from impaired IgE-mediated mast cell activation; thus, GATA2 represents a novel therapeutic target for clinical allergy. Copyright © 2019. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.jaci.2019.05.007
  3. PMID: 31102699
  4. View record in Web of Science®
  5. WOS: 000478789300033
  6. PII : S0091-6749(19)30624-4

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel